REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

Nishan Lamichhane  ¹     Nikolaos Melas  ²     Viktoria Bergqvist  ³     Swibreg Sweden  ⁴     Nils-Peter Ekholm  ⁵     Ola Olén  ⁶     Jonas F Ludvigsson  ⁷     Henrik Hjortswang  ⁸     Jan Marsal  ⁹     Carl Eriksson     Jonas Halfvarson    
¹ Örebro University, Örebro, Sweden
² Karlstad Central Hospital, Karlstad, Sweden
³ Skåne University Hospital, Lund, Sweden
⁴ SWIBREG, Götland, Sweden
⁵ Takeda Pharma, Kungsbacka, Sweden
⁶ Karolinska Institutet, Stockholm, Sweden
⁷ Örebro University Hospital, Örebro, Sweden
⁸ Linköping University Hospital, Linköping, Sweden
⁹ Lund University, Lund, Sweden

Session
Patient reported outcomes in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)